8-K: SI-BONE Reports Strong Q1 2024 Results, Raises Full-Year Revenue Guidance

SI-BONE, Inc. announced a 16% increase in worldwide revenue for Q1 2024 and raised its full-year revenue guidance to $164-$166 million.

Summary

• SI-BONE reported a 16% increase in worldwide revenue for the first quarter of 2024, reaching $37.9 million, compared to $32.7 million in the same period last year.
• U.S. revenue also grew by approximately 16%, totaling $35.4 million, up from $30.5 million in the first quarter of 2023.
• The company's gross margin was approximately 79%, a slight decrease from 82% in the prior year, due to procedure and product mix.
• Operating expenses increased by about 10% to $41.9 million, driven by higher commissions, R&D investments, and stock-based compensation.
• The operating loss increased by approximately 7% to $12.0 million, compared to $11.3 million in the same quarter of the previous year.
• Net loss improved by about 2% to $10.9 million, or $0.27 per diluted share, compared to a net loss of $11.1 million, or $0.32 per diluted share, in the first quarter of 2023.
• Adjusted EBITDA loss was nearly flat at $4.0 million compared to the same period last year.
• SI-BONE has updated its 2024 worldwide revenue guidance to a range of $164 million to $166 million, up from the previous guidance of $162 million to $165 million.
• This updated guidance implies a growth of approximately 18% to 20% compared to 2023, an increase from the previous implied growth of 17% to 19%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased guidance, and positive management commentary. However, the slight decrease in gross margin and increase in operating loss temper the overall optimism.

Positives

• SI-BONE experienced strong revenue growth in both worldwide and U.S. markets.
• The company has increased its full-year revenue guidance, indicating confidence in future performance.
• The number of active physicians using SI-BONE products has increased significantly.
• The company has achieved a major milestone of over 100,000 procedures performed worldwide.
• The successful completion of the first procedure with the smaller diameter iFuse Bedrock Granite implant is a positive development.
• The continuation of the NTAP for iFuse Bedrock Granite provides a stable reimbursement environment.

Negatives

• Gross margin decreased slightly to approximately 79% due to procedure and product mix.
• Operating expenses increased by approximately 10%, impacting profitability.
• The operating loss increased by approximately 7% year-over-year.
• Adjusted EBITDA loss remained nearly flat compared to the same period last year.

Risks

• The company's ability to introduce and commercialize new products and indications is a risk.
• Maintaining favorable reimbursement for procedures using its products is a risk.
• Economic weakness could impact patients' ability and desire to undergo elective procedures.
• Supply chain risks could affect the company's operations.
• Future capital requirements for new surgical systems could pose a challenge.
• The pace of normalization of the healthcare operating environment could impact procedure volumes.

Future Outlook

SI-BONE has updated its 2024 worldwide revenue guidance to be in the range of $164 million to $166 million, implying a growth of approximately 18% to 20% compared to 2023.

Management Comments

• Laura Francis, Chief Executive Officer, stated she is pleased with the solid start to the year and confident about revenue growth acceleration.
• She also noted the company is making significant progress towards its adjusted EBITDA breakeven goal.

Industry Context

SI-BONE's results reflect a continued demand for minimally invasive surgical solutions for sacropelvic disorders, aligning with the broader trend of increased adoption of advanced medical technologies in orthopedics and spine surgery. The company's focus on expanding its product portfolio and market reach positions it well within the competitive landscape of medical device companies.

Comparison to Industry Standards

• SI-BONE's 16% revenue growth in Q1 2024 is strong compared to some of its peers in the medical device industry, although specific comparisons are difficult without detailed competitor data.
• Companies like Globus Medical and NuVasive, which also operate in the spine and orthopedic space, have reported varying growth rates, with some experiencing similar growth and others facing headwinds.
• The gross margin of 79% is relatively healthy for a medical device company, but it is slightly lower than some industry leaders who may have higher margins due to product mix or scale.
• SI-BONE's focus on minimally invasive procedures and its strong clinical evidence base are key differentiators that could give it a competitive edge over companies with less robust clinical data.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and strong Q1 results.
• Employees may be motivated by the company's growth and positive outlook.
• Customers (surgeons and hospitals) will benefit from the continued innovation and product development.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company's financial health as stable.

Next Steps

• SI-BONE will host a conference call to discuss the first quarter 2024 financial results.
• The company will continue to focus on expanding its market opportunity in pelvic fixation.
• SI-BONE will continue to build on the success of iFuse 3D with the adoption of TORQ across all call points.

Key Dates

Keywords

SI-BONE, iFuse, Sacropelvic, Musculoskeletal, Medical Device, Revenue Growth, Pelvic Fixation, Gross Margin, EBITDA, NTAP